GoAI
Get started
Avalo Therapeutics, Inc. logo

Avalo Therapeutics, Inc.

AVTX

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$19.83

Market data unavailable

Aug 21, 3:55 PM ET

AVTX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

7

Overpriced

Momentum

56

Neutral

Sentiment

71

Bullish

Risk resilience

51

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Industry
Biotechnology
Sector
Healthcare
Headquarters
US

Market position

Volume
569.83K
Market cap
1.04B USD

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-4.18×
P/B (TTM)
1.93×
P/S (TTM)
17,667.39×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-16861.02%
Operating margin
-154844.07%
Net margin
-170055.93%

Financial health

Debt / equity
0×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends13466%-39665%-92795%-145925%Gross margin, FY2021: 72.38%Gross margin, FY2022: 80.98%Gross margin, FY2023: 33.26%Gross margin, FY2024: 182.99%Gross margin, FY2025: 100.00%Operating margin, FY2021: -1521.56%Operating margin, FY2022: -207.41%Operating margin, FY2023: -1421.57%Operating margin, FY2024: -15535.60%Operating margin, FY2025: -123601.69%Net margin, FY2021: -1563.10%Net margin, FY2022: -230.78%Net margin, FY2023: -1639.50%Net margin, FY2024: -7965.76%Net margin, FY2025: -132642.37%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 72.38%. Gross margin FY2022 80.98%. Gross margin FY2023 33.26%. Gross margin FY2024 182.99%. Gross margin FY2025 100.00%. Operating margin FY2021 -1521.56%. Operating margin FY2022 -207.41%. Operating margin FY2023 -1421.57%. Operating margin FY2024 -15535.60%. Operating margin FY2025 -123601.69%. Net margin FY2021 -1563.10%. Net margin FY2022 -230.78%. Net margin FY2023 -1639.50%. Net margin FY2024 -7965.76%. Net margin FY2025 -132642.37%.

Income trends

Revenue

59K USD-86.62%

Operating income

−72.93M USD-6.44%

Net income

−78.26M USD-122.78%
Income trends across reported periods28.29M USD−12.68M USD−53.65M USD−94.62M USDRevenue, FY2021: 5.4M USDRevenue, FY2022: 18.05M USDRevenue, FY2023: 1.92M USDRevenue, FY2024: 441K USDRevenue, FY2025: 59K USDOperating income, FY2021: −82.13M USDOperating income, FY2022: −37.44M USDOperating income, FY2023: −27.35M USDOperating income, FY2024: −68.51M USDOperating income, FY2025: −72.93M USDNet income, FY2021: −84.38M USDNet income, FY2022: −41.66M USDNet income, FY2023: −31.54M USDNet income, FY2024: −35.13M USDNet income, FY2025: −78.26M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 5.4M USD. Revenue FY2022 18.05M USD. Revenue FY2023 1.92M USD. Revenue FY2024 441K USD. Revenue FY2025 59K USD. Operating income FY2021 −82.13M USD. Operating income FY2022 −37.44M USD. Operating income FY2023 −27.35M USD. Operating income FY2024 −68.51M USD. Operating income FY2025 −72.93M USD. Net income FY2021 −84.38M USD. Net income FY2022 −41.66M USD. Net income FY2023 −31.54M USD. Net income FY2024 −35.13M USD. Net income FY2025 −78.26M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue59K USD441K USD1.92M USD18.05M USD5.4M USD
Cost of goods sold—−366K USD1.28M USD3.43M USD1.49M USD
Gross profit59K USD807K USD640K USD14.62M USD3.91M USD
Research and development50.08M USD52.08M USD13.78M USD31.31M USD59.84M USD
Selling, general, and administrative22.9M USD17.24M USD10.3M USD20.71M USD24.66M USD
Operating expenses72.98M USD69.32M USD27.99M USD52.06M USD86.04M USD
Interest income4.35M USD3.32M USD———
Interest expense——3.42M USD4.17M USD2.39M USD
Depreciation and amortization344K USD169K USD158K USD166K USD1.66M USD
Operating income−72.93M USD−68.51M USD−27.35M USD−37.44M USD−82.13M USD
Net income−78.26M USD−35.13M USD−31.54M USD−41.66M USD−84.38M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-5.84
FY2025
Latest fiscal-year revenue
59K USD
FY2025 · -86.62% year over year

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend229.48-701.48-1,632.44-2,563.4FY21FY22FY23FY24FY25

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend19.85M12.65M5.46M-1.74MFY21FY22FY23FY24FY25

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

10 ratings
Strong buy00%
Buy880%
Hold110%
Sell110%
Strong sell00%

Recent analyst actions

8 institutions
GuggenheimmaintainBuy
MizuhomaintainOutperform
Piper SandlermaintainOverweight
OppenheimerupgradePerformOutperform

Corporate actions

Corporate action history

Stock split

Effective Dec 29, 2023

1:240

Stock split

Effective Jul 8, 2022

1:12

AVTX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding AVTX

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
42.22M
Weight
0.37%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
30.58M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
21.34M
Weight
0.03%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
9.82M
Weight
0.01%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
Fidelity Enhanced Small Cap ETF logoFidelity Enhanced Small Cap ETFFESM
Market value
4.32M
Weight
0.07%
AUM
6.03B USD
Expense ratio
0.28%
Price / 1D
$47.94+0.80%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
4.28M
Weight
0.02%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
3.91M
Weight
0.03%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
3.78M
Weight
0.03%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%

Continue in GoAI

Research AVTX

research.disclaimer